Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Abstract

Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering therefrom by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 50 to 100 mg per patient.

1 . Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering from said syndromes, said method comprising administering to said patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 100 to 150 mg per patient. 
     
     
         2 . Method according to  claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride is in monohydrate form. 
     
     
         3 . Method according to  claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride is in monohydrate crystal form. 
     
     
         4 . Method according to  claim 1 , wherein said daily dosage is 100 mg per patient. 
     
     
         5 . Method according to  claim 1 , wherein said daily dosage is 150 mg per patient. 
     
     
         6 . Method according to  claim 1 , wherein said Philadelphia-negative myeloproliferative syndrome is polycythemia vera. 
     
     
         7 . Method according to  claim 1 , wherein said Philadelphia-negative myeloproliferative syndrome is essential thrombocythemia. 
     
     
         8 . Method according to  claim 1 , wherein said Philadelphia-negative myeloproliferative syndrome is primary myelofibrosis. 
     
     
         9 . Method according to  claim 1 , wherein said Philadelphia-negative myeloproliferative syndrome is secondary myelofibrosis. 
     
     
         10 . Method according to  claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, is not administered. in combination with other active principles. 
     
     
         11 . Method according to  claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, is administered in combination with at least one other cytostatic active principle.